TrialLancet (London, England)2022

Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.

Amanda Vrselja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.